Loading...

Amyris

Nasdaq:AMRS
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AMRS
Nasdaq
$312M
Market Cap
  1. Home
  2. US
  3. Materials
Company description

Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. The last earnings update was 121 days ago. More info.


Add to Portfolio Compare Print
  • Amyris has significant price volatility in the past 3 months.
AMRS Share Price and Events
7 Day Returns
-4.1%
NasdaqGS:AMRS
1.6%
US Chemicals
1.1%
US Market
1 Year Returns
-53.8%
NasdaqGS:AMRS
-10.6%
US Chemicals
4.7%
US Market
AMRS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Amyris (AMRS) -4.1% -22.2% -38.6% -53.8% -48% -94.4%
US Chemicals 1.6% 0.8% -4.2% -10.6% 16.2% 7.6%
US Market 1.1% 4.3% 2.9% 4.7% 37.7% 43.6%
1 Year Return vs Industry and Market
  • AMRS underperformed the Chemicals industry which returned -10.6% over the past year.
  • AMRS underperformed the Market in United States of America which returned 4.7% over the past year.
Price Volatility
AMRS
Industry
5yr Volatility vs Market

AMRS Value

 Is Amyris undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Amyris is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Amyris has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Amyris. This is due to cash flow or dividend data being unavailable. The share price is $3.08.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Amyris's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Amyris's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:AMRS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.52
NasdaqGS:AMRS Share Price ** NasdaqGS (2019-07-16) in USD $3.08
United States of America Chemicals Industry PE Ratio Median Figure of 68 Publicly-Listed Chemicals Companies 18.63x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Amyris.

NasdaqGS:AMRS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AMRS Share Price ÷ EPS (both in USD)

= 3.08 ÷ -3.52

-0.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amyris is loss making, we can't compare its value to the US Chemicals industry average.
  • Amyris is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Amyris's expected growth come at a high price?
Raw Data
NasdaqGS:AMRS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Chemicals Industry PEG Ratio Median Figure of 49 Publicly-Listed Chemicals Companies 1.43x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Amyris, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Amyris's assets?
Raw Data
NasdaqGS:AMRS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-2.43
NasdaqGS:AMRS Share Price * NasdaqGS (2019-07-16) in USD $3.08
United States of America Chemicals Industry PB Ratio Median Figure of 93 Publicly-Listed Chemicals Companies 2.09x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
NasdaqGS:AMRS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AMRS Share Price ÷ Book Value per Share (both in USD)

= 3.08 ÷ -2.43

-1.27x

* Primary Listing of Amyris.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Amyris has negative assets, we can't compare the value of its assets to the US Chemicals industry average.

Next steps:

  1. Take a look at our analysis of AMRS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Amyris's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Chemicals industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Amyris's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
  5. Amyris has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

AMRS Future Performance

 How is Amyris expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amyris has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.6%
Expected Chemicals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Amyris expected to grow at an attractive rate?
  • Unable to compare Amyris's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Amyris's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Amyris's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:AMRS Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
United States of America Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 4.9%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:AMRS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:AMRS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NasdaqGS:AMRS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 80 -213
2018-09-30 142 -86 -162
2018-06-30 151 -93 -136
2018-03-31 153 -101 -148
2017-12-31 143 -101 -93
2017-09-30 85 -140 -139
2017-06-30 87 -104 -116
2017-03-31 71 -84 -119
2016-12-31 67 -82 -97
2016-09-30 55 -78 -94
2016-06-30 37 -91 -151
2016-03-31 35 -106 -185

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Amyris is high growth as no earnings estimate data is available.
  • Unable to determine if Amyris is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:AMRS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Amyris Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:AMRS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NasdaqGS:AMRS Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.52
2018-09-30 -3.03
2018-06-30 -2.83
2018-03-31 -3.68
2017-12-31 -2.89
2017-09-30 -5.56
2017-06-30 -6.02
2017-03-31 -6.91
2016-12-31 -6.12
2016-09-30 -6.37
2016-06-30 -11.62
2016-03-31 -17.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Amyris will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of AMRS’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Amyris's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Materials companies here
  3. Amyris's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Amyris's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Amyris has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

AMRS Past Performance

  How has Amyris performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Amyris's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Amyris does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Amyris's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Amyris's 1-year growth to the US Chemicals industry average as it is not currently profitable.
Earnings and Revenue History
Amyris's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Amyris Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:AMRS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 80.42 -212.61 86.92
2018-09-30 141.65 -162.27 79.01
2018-06-30 150.98 -136.49 73.44
2018-03-31 153.46 -147.89 69.27
2017-12-31 143.45 -93.37 63.29
2017-09-30 85.10 -139.21 56.92
2017-06-30 87.44 -116.10 52.85
2017-03-31 71.36 -119.40 48.23
2016-12-31 67.19 -97.33 47.72
2016-09-30 54.80 -94.32 48.46
2016-06-30 36.85 -151.28 51.18
2016-03-31 35.09 -184.85 54.15
2015-12-31 34.15 -221.78 56.26
2015-09-30 35.89 -118.01 56.57 3.51
2015-06-30 43.64 -77.99 56.82 3.51
2015-03-31 45.11 -66.34 56.42 3.51
2014-12-31 43.27 2.29 55.44
2014-09-30 47.09 -195.16 56.18
2014-06-30 37.75 -182.72 54.88
2014-03-31 39.29 -186.11 55.62
2013-12-31 41.12 -235.11 57.05 4.28
2013-09-30 31.58 -139.18 60.02
2013-06-30 43.68 -135.28 64.32
2013-03-31 52.09 -143.21 71.83 -1.51
2012-12-31 73.69 -205.14 78.72
2012-09-30 109.38 -221.08 85.13 6.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Amyris has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Amyris has efficiently used its assets last year compared to the US Chemicals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Amyris improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Amyris's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Amyris has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

AMRS Health

 How is Amyris's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Amyris's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Amyris's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Amyris's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Amyris's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Amyris has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Amyris Company Filings, last reported 6 months ago.

NasdaqGS:AMRS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -179.44 209.91 45.35
2018-09-30 -205.59 171.12 19.05
2018-06-30 -253.98 171.40 14.18
2018-03-31 -291.21 163.06 24.08
2017-12-31 -199.71 165.38 57.06
2017-09-30 -195.41 164.65 17.61
2017-06-30 -186.52 167.70 6.63
2017-03-31 -211.25 223.92 2.49
2016-12-31 -183.51 229.80 28.52
2016-09-30 -162.50 179.10 2.30
2016-06-30 -154.18 184.88 2.51
2016-03-31 -156.79 174.65 9.27
2015-12-31 -158.46 156.98 13.51
2015-09-30 -141.47 158.76 11.90
2015-06-30 -227.77 288.37 12.12
2015-03-31 -185.92 247.08 44.95
2014-12-31 -125.06 236.17 43.42
2014-09-30 -180.64 233.14 68.60
2014-06-30 -139.68 225.16 90.21
2014-03-31 -112.49 181.99 49.11
2013-12-31 -135.85 155.66 8.30
2013-09-30 0.42 121.91 6.34
2013-06-30 20.28 110.12 12.92
2013-03-31 58.78 108.36 24.86
2012-12-31 66.23 105.53 30.69
2012-09-30 76.66 106.54 44.43
  • Amyris has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Amyris's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Amyris has less than a year of cash runway based on current free cash flow.
  • Amyris has less than a year of cash runway if free cash flow continues to grow at historical rates of 6.1% each year.
X
Financial health checks
We assess Amyris's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Amyris has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

AMRS Dividends

 What is Amyris's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Amyris dividends.
If you bought $2,000 of Amyris shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Amyris's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Amyris's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:AMRS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 56 Stocks 2.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:AMRS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Amyris has not reported any payouts.
  • Unable to verify if Amyris's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Amyris's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Amyris has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Amyris's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Amyris afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Amyris has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

AMRS Management

 What is the CEO of Amyris's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Melo
COMPENSATION $1,993,444
AGE 53
TENURE AS CEO 12.5 years
CEO Bio

Mr. John G. Melo has been the Chief Executive Officer at Amyris, Inc. since January 2007 and has been its President since June 2008. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior management positions of BP plc (formerly British Petroleum) from 1997 to 2006, mostly as President of U.S. Fuels Operations from 2004 to December 2006 and previously as Chief Information Officer of the refining and marketing segment from 2001 to 2003, Senior Advisor for e-business strategy to Lord Browne, BP's Chief Executive Officer, from 2000 to 2001 and Director of Global Brand Development from 1999 to 2000. In this last role, he helped develop the “Helios” re-branding effort. He successfully led a business transformation and significantly improved the financial performance at BP. He was with Ernst & Young, from 1996 to 1997 and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company and Alldata Corporation. Mr. Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. Mr. Melo serves on the Board of Directors for U.S. Oil, a $1.6 billion energy company and Cilion. He serves as a Director at BayBio and Venture, Inc and Renmatix, Inc. He has been a Director at Amyris, Inc. since January 2007. He served as a Director of KiOR, Inc from July 2010 to February 8, 2012. He served as a Director with Ernst & Young in San Jose, California Life Sciences Association and Bay Area Bioscience Association. Mr. Melo is a Member of the Economic Club of Chicago, The Chicago Club and The Chicago Council on Global Affairs. He serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was an appointed member to the U.S. section of the U.S.-Brazil CEO Forum.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • Insufficient data for John to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Amyris management team in years:

1.1
Average Tenure
55
Average Age
  • The average tenure for the Amyris management team is less than 2 years, this suggests a new team.
Management Team

John Melo

TITLE
President
COMPENSATION
$2M
AGE
53
TENURE
12.5 yrs

Eduardo Alvarez

TITLE
Chief Operating Officer
COMPENSATION
$799K
AGE
55
TENURE
1.8 yrs

Nicole Kelsey

TITLE
General Counsel & Secretary
COMPENSATION
$774K
AGE
52
TENURE
1.9 yrs

Kathy Valiasek

TITLE
Chief Business Officer
COMPENSATION
$880K
AGE
55
TENURE
0.1 yrs

Fernando de Castro Reinach

TITLE
Consultant
COMPENSATION
$57K
AGE
64
TENURE
1 yrs

Jon Wolter

TITLE
Interim Chief Financial Officer
AGE
69
TENURE
0.1 yrs

Tony Hughes

TITLE
Chief Accounting Officer
AGE
54
TENURE
1.1 yrs

Peter DeNardo

TITLE
Director of Investor Relations & Corporate Communications

Beth Baker Bannerman

TITLE
Senior Vice President of Corporate Communications & Engagement

Christine Ofori

TITLE
Chief People Officer
Board of Directors Tenure

Average tenure and age of the Amyris board of directors in years:

6.2
Average Tenure
62
Average Age
  • The tenure for the Amyris board of directors is about average.
Board of Directors

John Melo

TITLE
President
COMPENSATION
$2M
AGE
53
TENURE
12.5 yrs

John Doerr

TITLE
Independent Director
COMPENSATION
$61K
AGE
67
TENURE
13.2 yrs

Carole Piwnica

TITLE
Independent Director
COMPENSATION
$64K
AGE
61
TENURE
9.8 yrs

Steve Mills

TITLE
Independent Director
COMPENSATION
$2M
AGE
63
TENURE
0.9 yrs

R. Williams

TITLE
Independent Director
COMPENSATION
$80K
AGE
66
TENURE
6.2 yrs

Geoffrey Duyk

TITLE
Independent Director
COMPENSATION
$24K
AGE
60
TENURE
7.2 yrs

Patrick Pichette

TITLE
Member of Strategic Advisory Board
COMPENSATION
$47K
AGE
56
TENURE
6.2 yrs

Patrick Yang

TITLE
Independent Director
COMPENSATION
$53K
AGE
71
TENURE
5 yrs

Philip Eykerman

TITLE
Director
COMPENSATION
$52K
AGE
50
TENURE
2.2 yrs

Frank F. Kung

TITLE
Director
COMPENSATION
$22K
AGE
70
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Amyris individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. May 19 Buy Vivo Capital, LLC Company 29. Apr 19 29. Apr 19 913,529 $4.76 $4,348,398
26. Apr 19 Buy L. Doerr Individual 24. Apr 19 24. Apr 19 2,832,440 $5.12 $14,502,093
18. Apr 19 Buy L. Doerr Individual 15. Apr 19 15. Apr 19 6,732,369 $2.87 $19,321,899
15. Dec 18 Buy Eduardo Alvarez Individual 13. Dec 18 13. Dec 18 11,834 $4.23 $50,058
27. Nov 18 Buy Kathleen Valiasek Individual 27. Nov 18 27. Nov 18 23,000 $4.37 $100,574
07. Sep 18 Buy Eduardo Alvarez Individual 05. Sep 18 05. Sep 18 11,877 $8.45 $100,326
22. Aug 18 Buy Kathleen Valiasek Individual 22. Aug 18 22. Aug 18 14,000 $7.20 $100,800
22. Aug 18 Sell Vivo Capital, LLC Company 17. Aug 18 17. Aug 18 -2,439,848 $6.22 $-15,172,927
15. Aug 18 Buy Patrick Yang Individual 13. Aug 18 13. Aug 18 15,000 $7.66 $114,900
13. Aug 18 Buy Patrick Yang Individual 09. Aug 18 09. Aug 18 10,000 $7.71 $77,100
X
Management checks
We assess Amyris's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Amyris has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

AMRS News

Simply Wall St News

What Kind Of Shareholder Appears On The Amyris, Inc.'s (NASDAQ:AMRS) Shareholder Register?

So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Our analysis of the ownership of the company, below, shows that. … institutions own shares in the company.

Simply Wall St -

Amyris Inc's (NASDAQ:AMRS) Shift From Loss To Profit

With the latest financial year loss of -US$93m and a trailing-twelve month of -US$136m, the US$454m market-cap amplifies its loss by moving further away from its breakeven target? … The most pressing concern for investors is AMRS’s path to profitability – when will it breakeven. … In this article, I will touch on the expectations for AMRS’s growth and when analysts expect the company to become profitable

Simply Wall St -

Breaking Down Amyris Inc's (NASDAQ:AMRS) Ownership Structure

In this article, I'm going to take a look at Amyris Inc’s (NASDAQ:AMRS) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Ownership structure of a company has been found to affect share performance over time. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Was Amyris Inc's (NASDAQ:AMRS) Earnings Growth Better Than The Industry's?

After looking at Amyris Inc's (NASDAQ:AMRS) latest earnings announcement (31 December 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … Check out our latest analysis for Amyris Commentary On AMRS's Past Performance To account for any quarterly or half-yearly updates, I use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … NasdaqGS:AMRS Income Statement May 14th 18 We can further analyze Amyris's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Who Are The Major Shareholders Of Amyris Inc (NASDAQ:AMRS)?

AMRS insiders are also influential stakeholders with 7.14% ownership in the company. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Another group of owners that a potential investor in AMRS should consider are private companies, with a stake of 0.048%.

Simply Wall St -

Amyris Inc's (NASDAQ:AMRS) Profit Outlook

Many investors are wondering the rate at which AMRS will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for AMRS’s growth and when analysts expect the company to become profitable. … Should the business grow at a slower rate, it will become profitable at a later date than expected. … For a more comprehensive look at AMRS, take a look at AMRS’s company page on Simply Wall St.

Simply Wall St -

Should You Be Holding Amyris Inc (NASDAQ:AMRS) Right Now?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Check out our latest analysis for Amyris An interpretation of AMRS's beta Amyris’s beta of 0.5 indicates that the company is less volatile relative to the diversified market portfolio. … AMRS's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns.

Simply Wall St -

Should Amyris Inc's (NASDAQ:AMRS) Recent Earnings Decline Worry You?

Examining Amyris Inc's (NASDAQ:AMRS) past track record of performance is a useful exercise for investors. … View our latest analysis for Amyris Did AMRS perform worse than its track record and industry? … Amyris's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story.

Simply Wall St -

Is Amyris Inc's (AMRS) CEO Paid Enough Relative To Peers?

Furthermore, Melo's pay is also made up of non-cash items, which means that fluxes in AMRS's share price can impact the actual level of what the CEO actually receives. … Normally I would look at market cap and earnings as a proxy for performance, however, AMRS's negative earnings reduces the usefulness of my formula. … Regardless of whether Melo's pay is above or below peers, the more important factors to look at is AMRS's track record of performance and future outlook moving forward.

Simply Wall St -

Who Are Amyris Inc's (AMRS) Major Shareholders?

Check out our latest analysis for Amyris NasdaqGS:AMRS Ownership Summary Nov 9th 17 Institutional Ownership With an institutional ownership of 15.44%, AMRS can face volatile stock price movements if institutions execute block trades on the open market, more so, when there are relatively small amounts of shares available on the market to trade Although AMRS has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. … Private Company Ownership Another important group of owners for potential investors in AMRS are private companies that hold a stake of 0.05% in AMRS. … The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

AMRS Company Info

Description

Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Details
Name: Amyris, Inc.
AMRS
Exchange: NasdaqGS
Founded: 2003
$311,655,153
101,186,738
Website: http://www.amyris.com
Address: Amyris, Inc.
5885 Hollis Street,
Suite 100,
Emeryville,
California, 94608,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AMRS Common Stock Nasdaq Global Select US USD 28. Sep 2010
DB 3A01 Common Stock Deutsche Boerse AG DE EUR 28. Sep 2010
Number of employees
Current staff
Staff numbers
414
Amyris employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/17 00:21
End of day share price update: 2019/07/16 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.